Quality of evidence: D
Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin
Authors: Hu H et al
Journal: European Heart Journal
Objectives: Suggest a drug therapy for SARS-CoV-2 patients with myocarditis
Strength of evidence: Low (case-report)
Methods/publication type:
Case-report
A 37-year-old man with fulminant myocarditis due to SARS-CoV-2, with cardiogenic shock and pulmonary infection.
Treatment: Methylprednisolone to reduce inflammation (200 mg / day for 4 days)
Immunoglobulin to regulate immune status (20g / day for 4 days)
noradrenaline to increase blood pressure, diuretic (Toracemide or Furosemide) to reduce afterload
Milrinone to increase cardiac contractility
Piperacillin-Sulbactam as an anti-infective
Pantoprazole to inhibit stomach acidity
Highlights :
After 3 weeks of treatment, all markers of myocardial lesions returned to normal
Early treatment with anti-inflammatory glucocorticoids and immunoglobulins might be of importance for young patients with fulminant myocarditis
Comments